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A B S T R A C T
Expression of Cathepsin D (Cath D) in some primary neuroepithelial brain tumors and its prognostic value were
studied. The research included 65 samples of human primary neuroepithelial brain tumors. There were 50 glial tumors
(10 diffuse astrocytomas (DA), 15 anaplastic astrocytomas (AA), 25 glioblastomas (GB), 15 embryonic tumors (15 me-
dulloblastomas (MB) as well as 5 samples of normal brain tissue. Immunohistochemical method was applied to monitor
diffuse positive reaction in the cytoplasm of brain tumor cells, endothelial cells and tumor stromal cells and showed dif-
fuse positive reaction for Cath D in the cytoplasm of brain tumor cells, endothelial cells and stromal cells in all analyzed
samples of DA, AA, GB and MB as well as in microglial cells, neurons and in endothelial cells in all analyzed samples of
normal brain tissue. Qualitative analysis of Cath D expression in the cytoplasm of brain tumor cells and endothelial cells
as well as the percentage of brain tumor cells, endothelial cells and stromal cells immunopositive for Cath D showed that
there was difference between analyzed brain tumor groups, but according to statistical tests the difference was not statis-
tically significant. Survival correlated with the percentage of stromal cells immunopositive for Cath D. Survival progno-
sis was influenced by the percentage of stromal cells immunopositive for Cath D and tumor grade. The obtained results
singled out the percentage of stromal cells immunopositive for Cath D as an independent parameter. The results of this
research on the prognostic value of Cath D in some primary brain tumors of neuroepithelial origin indicate that there is
real possibility to use Cath D as an independent prognostic factor in human glioma progression and thus open up possi-
bilities for further scientific research.
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Introduction
Invasion and metastasis are special features of malig-
nant tumors1. Ability of malignant cells to invade the
vascular and lymphatic system facilitates the spreading
of a malignant tumor. Certain types of malignant tumors
do not metastasise, such as for example most types of pri-
mary malignant tumors of central nervous system (CNS).
However, some CNS tumors are extremely invasive and
agressive in their primary sites. Namely, it is characteris-
tic for brain tumors to metastasise within the CNS, while
spreading to other organs is extremely rare. Not a single
case of spreading from the CNS to other organs was de-
scribed in pylocitic astrocytoma (PA) and diffuse astro-
cytoma (DA), while in anaplastic astrocytoma (AA) and
glioblastoma (GB) there were a few cases where the tu-
mor spread out of the CNS (lungs, regional lymph nodes,
bones), mostly in advanced tumors that were not surgi-
cally treated2. Medulloblastoma (MB) usually spreads wi-
thin the CNS, but also into the pelvis and lymph nodes.
Cathepsins (Cath) (B, C, D, E, G, H, K, L, S) are
intracellular proteinases that catalyse the peptide link
splitting inside the peptide chain. They are most fre-
quently found in lysosomes and in physiological condi-
tions they act intracellulary3,4. Up-to-date research has
proved that they are included in tissue barriers destruc-
tion in the host during the invasion process in malignant
tumors. The recent research on tumor cells biology fo-
cuses on the role of enzymes that destruct the extrace-
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llular matrix, especially Cath D, lysosomal acid pro-
teinase, which has the role of proteolytic enzyme in
tumor invasion and also shows mitogen effect in vitro5.
Namely, some studies have shown that Cath D may be re-
sponsible for malignant tumors invasion and metastasis,
either directly by destructing the extracellular matrix, or
indirectly by activating cysteine proteases such as pro-
cathepsin B, H and L and their processing to the mature
form, or by inactivating cystine protease inhibitors5. A
large number of studies have also shown that Cath D is
widespread in both animal and human tumors in differ-
ent proportion and moreover, that there is disturbed pro-
duction and secretion as well as increased activity of this
enzyme in these tumors in comparison to normal tis-
sue6,7. Cath D might be one of the most crucial enzymes
involved in the cascade process of metastasis develop-
ment. Most studies on the role of Cath D in tumor inva-
sion and metastasis have been carried out in vitro on the
human breast carcinoma cells8,9. Immunohistochemical
and clinical studies have found Cath D in the tissue of la-
ryngeal carcinoma, colorectal carcinoma, ovarian carcino-
ma, thyroidal carcinoma and malignant melanoma10,11.
There have been very few immunohistochemical and
clinical studies on activity of Cath D in CNS tumors12–15.
It may be assumed that primary malignant CNS tumors
rarely metastasise because their cells (in the course of
evolutional differentiation) have lost the ability to syn-
thetise proteases, including Cath D, while the local in-
vasivity of these tumors is the consequence of the brain
tissue structure without stromal barriers to tumor sprea-
ding.
The aim of this research was to determine the expres-
sion of Cath D in some primary neuroepithelial brain tu-
mors of various differentiation levels using immuno-
histochemical methods and also to determine the prognos-
tic value of Cath D, that is its applicability in survival
prognosis.
Materials and Methods
Collection and analysis of primary neuroepithelial
brain tumors tissue samples
Cath D expression was studied on 65 samples of pri-
mary brain tumors of neuroepithelial origin embedded in
paraffin blocks obtained from Osijek University Hospital
Center, Department of Pathology and Forensic Medicine
(28 samples) and from Zagreb University Hospital Cen-
tre, Clinical Institute of Pathology, Department of Neu-
ropathology (37 samples). Only the neuroepithelial tu-
mor samples that fulfill all histological criteria according
to WHO classification of tumors in the nervous system
were studied16,17. According to these criteria the research
was carried out on 10 DAs, 15 AAs, 25 GBs and 15 MBs.
Normal brain tissue without pathological substrate was
used as control, which included 5 samples of healthy
brain tissue embedded in paraffin blocks. These samples
were obtained from authopsy specimens from the collec-
tion of Osijek University Hospital Center, Department of
Pathology and Forensic Medicine.
Tissue preparation for light microscopic analysis
The samples of neuroepithelial brain tumors obtained
by surgical procedures were fixed for 12–24 hours in 10%
puffered formalin and then embedded in paraffin blocks.
Standard HE staining was applied to estimate morpho-
logical structure of tumor tissue regarding the shape of
cells and nuclei, degenerative changes and chromatin
content in the cytoplasm. Application of Mallory’s tri-
chrome staining technique gave better insight into fibro-
vascular (mesenchymal) stroma assessment.
Immunohistochemical staining of preparations
with monoclonal antibodies against
Cath D
Primary rabbit anti-human antibody against Cath D
(DAKO N 1625) was used for immuno-histochemical
staining diluted 1 : 200. Standard indirect ABC tech-
nique was applied. Proteolysis was carried out with
proteolytic enzyme, 0.1% pronase (DAKO S 2013) at tem-
perature of 37° C18.
Immunohistochemical staining of preparation
with monoclonal antibody against macrophages
(CD 68)
Primary muscular antihuman antibody against ma-
crophages (CD 68) (DAKO N 1577) was used for im-
munohistochemical staining. Standard indirect ABC te-
chnique was applied. Proteolysis was carried out at high
temperature – using microwaves for heating18.
Analysis of immunohistochemical preparations
Following the WHO recommendations, standard (HE)
preparations were analyzed to determine their histo-
logical type and grade of primary brain tumor of neuro-
epithelial origin. Diffuse positive reaction for Cath D in
the cytoplasm was determined qualitatively and quanti-
tatively for the following three parameters:
1. diffuse positive immunohistochemical reaction for
Cath D in the cytoplasm of brain tumor cells;
2. diffuse positive immunohistochemical reaction for
Cath D in the cytoplasm of the tumor stromal
cells;
3. diffuse positive immunohistochemical reaction for
Cath D in the cytoplasm of endothelial cells.
Qualitative analysis
For each parameter qualitative analysis of diffuse cy-
toplasmic immunohistochemical reaction for Cath D was
performed in 10 microscopic high power fields (HPF, mi-
croscope magnification ´400, Olympus), and graded in
the following way: Score 0=(0) – negative, there was no
diffuse cytoplasmic positive immunohistochemical reac-
tion for Cath D, Score 1=(+) – weak, there was a weak
diffuse cytoplasmic reaction positive immunohistoche-
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mical reaction for Cath D, Score 2=(++) – moderate,
there was medium strong diffuse cytoplasmic positive
immunohistochemical reaction for Cath D, Score 3=
(+++) – extremely strong, there was extremely strong
diffuse cytoplasmic positive immunohistochemical reac-
tion for Cath D.
Quantitative analysis
Using »image analyser«, a computer system for image
analysis produced by VAMS company, Zagreb, Croatia,
for each of the analyzed parameters the number of cells
immunopositive for Cath D was measured and then ex-
pressed as percentage of the number of analyzed cells in
10 HPF.
Statistical analysis
In description of continuous numerical variables ari-
thmetic mean was used (X), minimum, maximum, stan-
dard deviation (SD), standard error (SE) and variance
(s2), while in description of ordinal and nominal variables
relative frequency distribution was used. Parametric cor-
relation (Pearson) and non-parametric correlations (Ken-
dall’s t-b, Spearman’s r) as well as calculation of statisti-
cal significance were used to determine the correlation
between the tumor grade, survival, results of qualitative
and quantitative analysis of Cath D expression in ana-
lyzed parameters described previously. Multiple regres-
sion was done using dependent variable (tumor grade/
survival) and independent variables (results of qualita-
tive and quantitative analysis of Cath D expression) in
analyzed parameters. Survival analysis was carried out
using Kaplan-Meier curves (KM curves) of cumulative
survival proportion and Long-rank test for results of
qualitative and quantitative analysis of Cath D expres-
sion in analyzed parameters. Except for the survival
analysis that was carried out using KM curves of cum-
mulative survival proportion and Long-rank test, the si-
multaneous influence of all parameters (sex, age, tumor
grade, results of qualitative and quantitative analysis of
Cath D expression in analyzed parameters) on survival
prognosis was analyzed using the method of multivariant
regression, that is Cox’s regression test19.
Results
The research included 65 surgically treated patients
(42 or 64.6% male and 23 or 35.4% female). The youngest
patient was 1 year old and the oldest was 74 (X=43.969,
SD=21.641, SE=2.684). In 46 (70.8%) cases patients
were completely followed (until death), and 19 (29.2%)
were censured patients (death has not occured yet). The
shortest survival was 3 days and the longest 2094 days
(X=580.923, SD=600.318, SE=74.460).
Immunohistochemical analysis showed diffuse posi-
tive reaction for Cath D in the cytoplasm of brain tumor
cells, endothelial cells and the tumor stromal cells in all
analyzed samples of DA (WHO grade II), AA (WHO grade
III), GB (WHO grade IV) and MB (WHO grade IV) as well
as in the microglial cells, neurons and endothelial cells in
all analyzed samples of normal brain tissue. Qualitative
analysis showed that expression of Cath D in the cyto-
plasm of brain tumor cells and in the cytoplasm of endo-
thelial cells gradually declines with higher tumor grade
(the result was not statistically significant), while there
was no difference in expression of Cath D in the stromal
cells regarding the grade. The percentage of brain tumor
cells and endothelial cells immunopositive for Cath D
gradually declines with higher tumor grade, while the
percentage of the cells adjacent to blood vessels wall
gradually rises with higher tumor grade (the result was
not statistically significant).
Parametric correlation (Pearson) (Table 1) and non-
-parametric correlations [Kendall’s t-b (Table 2), Spear-
man’s r (Table 3)] showed that Cath D expression level
in the cytoplasm of brain tumor cells, endothelial cells
and the stromal cells does not correlate with the grade of
analyzed brain tumors. Parametric correlation (Pearson)
(Table 1) and non-parametric correlations [Kendall’s t-b
(Table 2), Spearman’s r (Table 3)] also showed that the
percentage of Cath D positive brain tumor cells, endothe-
lial cells and the stromal cells does not correlate with the
grade of analyzed brain tumors.
Parametric correlation (Pearson) (Table 1) and non-
-parametric correlations [Kendall’s t-b (Table 2), Spear-
man’s r (Table 3)] showed that the brain tumor grade
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TABLE 1
PRESENTS THE RESULTS OBTAINED BY PARAMETRIC
CORRELATION (PEARSON) AND CALCULATION OF
STATISTICAL SIGNIFICANCE
1 2 3
1 Pearson’s correlation coefficient 1.000 –0.227 –0.132
Statistical significance (p) 0.034 0.148
2 Pearson’s correlation coefficient –0.227 1.000 –0.584
Statistical significance (p) 0.034 0.001
3 Pearson’s correlation coefficient –0.132 –0.584 1.000
Statistical significance (p) 0.148 0.001
1 tumor grade, 2 survival, 3 percentage of cells adjacent to blood
vessels wall immunopositive for Cath D
TABLE 2
PRESENTS RESULTS OBTAINED BY NON-PARAMETRIC
CCORRELATION (KENDALL’S T-B) AND CALCULATION OF
STATISTICAL SIGNIFICANCE
Kendall’s t-b 1 2 3
1 Correlation coefficient 1.000 –0.231 –0.135
Statistical significance (p) 0.019 0.158
2 Correlation coefficient –0.231 1.000 –0.376
Statistical significance (p) 0.019 0.001
3 Correlation coefficient –0.35 –0.376 1.000
Statistical significance (p) 0.58 0.001
1 tumor grade, 2 survival, 3 percentage of cells adjacent to blood
vessels wal immunpositive for Cath D
and the percentage of the Cath D positive stromal cells
correlate with the survival. Multiple regression showed
that the survival, Cath D expression level, as well as the
percentage of Cath D positive brain tumor cells, endothe-
lial cells and tumor stromal cells do not correlate with
the grade of analyzed brain tumors. Multiple regression
showed that survival correlates only with the percentage
of Cath D positive stromal cells. KM curves (Graph 1)
showed that the percentage of Cath D positive stromal
cells influences the survival prognosis. Cox’s regression
test (Table 4) showed that both, the percentage of Cath D
positive stromal cells, and the tumor grade influence sur-
vival prognosis.
Thus, based on the obtained results it can be con-
cluded that Cath D is immunoreactive in all the struc-
tures of analyzed brain tumors of neuroepithelial origin
and that its immunoreactivity in the analyzed tumors
does not change depending on the differentiation level.
Cath D immunoreactivity in the stromal cells in all ana-
lyzed tumors has statistically significant correlation with
survival prognosis.
Discussion and Conclusion
Considering the encouraging results obtained by stu-
dying the prognostic value of Cath D in breast carci-
noma, colorectal carcinoma, ovarian carcinoma, thyroid
carcinoma and malignant melanoma8–11,20, more research
on prognostic value of not only Cath D, but of other
cathepsins, such as Cath B, Cath H and Cath L in pri-
mary CNS tumors was initiated12–15,21–30. The researches
that have been conducted up to now, both biochemical
and histochemical, studied the role of Cath B in tumor
invasion and metastasis, as well as prognostic value of
Cath B in primary CNS tumors21,23–28. The research re-
sults on gliomas, up-to-now most frequently studied pri-
mary CNS tumors, and also in some other, less studied
primary brain tumors, showed increase of both the con-
tent and the expression of analyzed proteolytic enzymes,
such as collagenase, glycodase, plasminogen activator
and heparinase, as well as Cath B, L and H which are
considered to be associated with the progression and in-
vasion of analyzed primary brain tumors21,23–31.
A small number of biochemical and immunohisto-
chemical researches were conducted that studied the
content and expression of Cath D in primary CNS tu-
mors. Robson et al. confirmed the presence of Cath D in
normal human brain tissue as well as in primary CNS tu-
mors. The results were not quantified, only cellular dis-
tribution of Cath D was studied15. Warich et al. study the
expression of Cath D in primary CNS tumors, that is in
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TABLE 3
PRESENTS RESULTS OBTAINED BY NON-PARAMETRIC
CORRELATION (SPEARMAN’S r) AND CALCULATION OF
STATISTICAL SIGNIFICANCE
Spearman’s r 1 2 3
1 Correlation coefficient 1.000 –0.327 –0.197
Statistical significance (p) 0.008 0.090
2 Correlation coefficient –0.327 1.000 –0.532
Statistical significance (p) 0.008 0.001
3 Correlation coefficient –0.197 –0.532 1.000
Statistical significance (p) 0.090 0.001
1 tumor grade, 2 survival, 3 percentage of cells adjacent to blood
vessels wall immunopositive for Cath D
TABLE 4
COMPUTER PRINT-OUT OF RESULTS OBTAINED BY THE METHOD OF MULTIVARIANT REGRESSION, THAT IS COX’S REGRESSION
TEST FOR DEPENDANT VARIABLE – SURVIVAL AND INDEPENDENT VARIABLES
B S.E. Wald df Sig R Exp (B)
I 0.2198 0.3250 0.4571 1 0.499 0.0000 1.2458
II 0.0506 0.0153 10.9694 1 0.001 0.1633 1.0519
III –2.2569 0.8963 6.3408 1 0.012 –0.1136 0.1047
IV –0.3012 0.6452 0.2179 1 0.641 0.0000 0.7400
V –0.0211 0.7209 0.0009 1 0.977 0.0000 0.9791
VI 8.9149 3 0.030 0.0931
VII –0.2498 0.2935 0.7245 1 0.395 0.0000 0.7789
VIII 0
IX 0.2424 0.3205 0.5719 1 0.450 0.0000 1.2743
X 6.425E-04 0.0124 0.0027 1 0.959 0.0000 1.0006
XI 0.0370 0.0083 19.8237 1 0.001 0.2302 1.0377
XII –0.0052 0.0123 0.1758 1 0.675 0.0000 0.9949
I – sex, II – age, III – DA – WHO grade II, IV – AA – WHO grade III, V – GB – WHO grade IV, VI – MB – WHO grade IV, VII – Cath D ex-
pression level in the cytoplasm of brain tumor cells, VIII – Cath D expression level in the cytoplasm of cells adjacent to blood vessels
wall, IX – Cath D expression level in the cytoplasm of endothelial cells, X – percenatge of brain tumor cells immunopositive for Cath D,
XI – percentage of adjacent blood vessel wall cells immunopositive for Cath D, XII – percenatage of endothelial cells immunopositive
for Cath D
glial tumors of various differentiation levels. The analy-
sis showed that the expression of Cath D as well as the
percentage of positive brain tumor cells were signifi-
cantly higher in low grade astrocytoma and lower in AA
and GB. According to their results, the expression of
Cath D in brain tumor cells does not correlate with ma-
lignant progression and histological grade of human glio-
ma14. However, these results differ from those obtained
by Sivaparvathi et al. According to this research the con-
tent and expression of Cath D were the highest in GB,
lower in AA and the lowest in diffuse low grade astrocy-
toma and normal brain tissue. The authors concluded
that the content and expression of Cath D in brain tumor
cells correlate with malignant progression and histolo-
gical grade of human gliomas and that they are associ-
ated with their invasion12.
In view of all this, and with special regard to described
predictive value of Cath D as well as of other cathepsins
in some other human cancerous tumors, we wanted not
only to study its expression in most frequent primary
neuroepithelial brain tumors, but also to determine if
Cath D expression in these tumors has prognostic value,
which was not studied up to this point. Based on the past
experience from the literature, we designed our own re-
search model to study the expression of Cath D in most
frequent primary neuroepithelial brain tumors and to
determine if it has prognostic value. The research was
carried out applying immunohistochemical method and
it included human primary neuroepithelial brain tumors,
that is gliomas of various differentiation levels and MB,
as well as normal human brain tissue samples. Since the
past data on MB showed that it frequently spreads wi-
thin, but also out of the CNS, and also considering that
MB was not included in the past research on the expres-
sion of Cath D, we decided to include it in this research.
Namely, in view of the results obtained by Warich et al.
we expected the expression of Cath D in MB to be either
signficantly lower or significantly higher than in glial tu-
mors, especially if it was in compliance with the results
obtained by Sivaparvathi et al., since MB has far more in-
vasive phenotype than glial tumors12,14.
We considered it significant to study the expression of
Cath D in the tumor stromal cells, especially in macro-
phages, since they take part not only in angiogenesis, but
also in the proliferation of tumor cells. The results of this
study confirmed the expression of Cath D in all parame-
ters included in analysis of primary brain tumors of
neuroepithelial origin, as well as in normal brain tissue
samples, which is partly in compliance with the results
obtained by Warich et al.14 and Sivaparvathi et al.12 Cath
D expression level in the cytoplasm of brain tumor cells
and endothelial cells gradually declines with higher tu-
mor grade and it is the lowest in MB, but, according to
statistical tests, it was not statistically significant, while
there was no difference in Cath D expression level in the
cytoplasm of stromal cells regarding the tumor grade. As
in the past research12,14–15 Cath D expression level was
not studied in the cytoplasm of brain tumor cells, endo-
thelial cells and the stromal cells, we believe that the re-
sults obtained in our research may be the consequence of
lower content and expression of Cath D, which is accord-
ing to Warich et al.14 explained by concomitant loss of
regular proteins in the cytoskeleton in advanced ana-
plasia, that is in higher grade tumors, which reduces the
need for the presence of digestive protelytic enzyme, that
is Cath D. This explanation is supported by Cath D ex-
pression level obtained by qualitative analysis, which is
the same in the cytoplasm of the stromal cells and of
macrophages that do not depend on anaplasia of tumoral
and endothelial cells and therefore do not lose expression
of Cath D.
The percentage of brain tumor cells immunopositive
for Cath D gradually declines with higher tumor grade
and it is the lowest in MB. However, statistical tests
showed that it is not statistically significant. The situa-
tion is the same with the percentage of endothelial cells
immunopositive for Cath D, which does not support the
results obtained by Warich et al.14 In their research endo-
thelial cells were not immunopositive for Cath D. How-
ever, we would like to focus attention on the parameter
nobody studied so far, namely the tumor stromal cells,
where the situation is quite different. Namely, the per-
centage of cells adjacent to blood vessels wall immuno-
positive for Cath D becomes higher with higher tumor
grade, but only in glial tumors. It was the highest in ana-
lyzed glioblastomas, but statistical tests showed that it
was not statistically significant. We expected the percent-
age of Cath D immunopositive stromal cells to be the
highest in MB because of its malignancy, but it was the
lowest, which was quite surprising. We cannot offer ade-
quate explanation for this result. On the other hand,
higher tumor grade in glial tumors correlates with hi-
gher percentage of Cath D immunopositive stromal cells,
which may be explained by the fact learned from numer-
ous previous studies that malignant tumor cells not only
produce and secrete various protelytic enzymes but also
probably stimulate host’s cells, in this case macrophages,
to produce Cath D. These results confirm the significance
of the supporting stroma not only for the tumor growth
but also for its invasive and locally agressive develop-
ment32–37. The results of our research show that only the
expression of Cath D in the stromal cells in glial tumors
correlates with the malignant progression and their hi-
stological grade.
Our intention was not only to study the expression of
Cath D in most frequent primary brain tumors of neuro-
epithelial origin but also to determine if Cath D has prog-
nostic value in these tumors. Statistical analysis showed
that the survival correlates only with the percentage of
Cath D immunopositive stromal cells, while it does not
correlate with other analyzed parameters. This correla-
tion is negative and it shows that lower percentage of
Cath D immunopositive stromal cells correlates with lon-
ger survival. However, since Pearson’s coefficient of cor-
relation is more than 0.50, it is considered that this cor-
relation is significant and that it has practical meaning,
which is also confirmed by multiple regression. KM cur-
ves of cumulative survival proportion and Long-rank test
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also showed that only the percentage of Cath D immuno-
positive stromal cells influences the survival prognosis.
In the end, to analyze the simultaneous influence of
all analyzed parameters (sex, age, tumor grade, Cath D
expression level in all analyzed cells and the percentage
of all analyzed cells immunopositive for Cath D) on sur-
vival prognosis, the method of multivariant regression,
that is Cox’s regression test, was applied. It showed that
age, histological type, tumor grade and percentage of
Cath D immunopositive stromal cells are independent
parameters. It is evident from the obtained results that
Cath D is immunoreactive in all structures of analyzed
brain tumors of neuroepithelial origin, that immuno-
reactivity of Cath D in analyzed tumors does not differ
depending on the differentiation level and that only the
immunoreactivity of Cath D in stromal cells in analyzed
tumors significantly correlates with the survival progno-
sis. The results of this research on prognostic value of
Cath D in some primary brain tumors of neuroepithelial
origin indicate that Cath D may be used as an independ-
ent prognostic factor in progression of human gliomas
and thus offer new possibilities for scientific research.
In recent study by Fukuda et al.38 the results of
real-time quantitative reverse transcription-PCR analy-
sis showed that Cath D transcript levels became signifi-
cantly higher as glioma grade advanced. The low expres-
sion of cath D significantly correlated with long survival
of their glioma patients. Measurement of the serum Cath
D concentrations showed a significant increase in the pa-
tients with high-grade gliomas as compared with the
low-grade tumors. These results collectively suggest that
cathepsin D could be a potential serum marker for the
prediction of aggressive nature of human gliomas.
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KATEPSIN D I NJEGOVA PROGNOSTI^KA VRIJEDNOST U NEUROEPITELNIM TUMORIMA
MOZGA
S A @ E T A K
U ovom radu prou~avane su ekspresija i prognosti~ka vrijednost katepsina D (Cath D) u nekim primarnim neuro-
epitelnim tumorima mozga. Istra`ivanje je uklju~ivalo 65 uzoraka humanih neuroepitelnih mo`danih tumora: 50 glija-
lnih tumora (10 difuznih astrocitoma (DA), 15 anaplasti~nih astrocitoma (AA), 25 glioblastoma (GB), 15 embrionalnih
tumora, 15 meduloblastoma (MB) kao i 5 uzoraka normalnog tkiva mozga. Imunohistokemijska metoda koja je pri-
mjenjena pokazala je difuznu pozitivnu reakciju na Cath D u citoplazmi mo`danih tumorskih, endotelnih, tumorskih
stromalnih stanica u svim analiziranim uzorcima DA, AA, GB, MB te u stanicama mikroglije, neuronima i endotelnim
stanicama u svim uzorcima normalnog mo`danog tkiva. Kvalitativna analiza ekspresije Cath D u citoplazmi tumorskih
stanica mozga, stanica endotela i postotak mo`danih tumorskih, endotelnih te stromalnih stanica imunopozitivnih na
Cath D pokazali su razliku izme|u prou~avanih grupa mo`danih tumora koja se uspostavila statisti~ki bezna~ajnom.
Pre`ivljenje je pozitivno koreliralo s postotkom stromalnih stanica imunopozitivnih na Cath D, dok je prognoza pre-
`ivljenja ovisila o postotku stromalnih stanica pozitivnih na Cath D i gradusu tumora. Dobiveni rezultati istaknuli su
postotak stanica strome imunopozitivnih na Cath D kao neovisni parametar. Rezultati ovog istra`ivanja vezani uz
prognosti~ku vrijednost Cath D u nekim primarnim neuroepitelnim tumorima mozga ukazuju na stvarnu mogu}nost
upotrebe Cath D kao neovisnog prognosti~kog faktora u progresiji humanih glioma i otvaraju mogu}nosti za daljnja
znanstvena istra`ivanja.
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